Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells

Inclusion Criteria: * Type 2 Diabetes * Oral antidiabetic therapy * Age 35 - 70 * 6,5%\< HbA1c ≤ 9% * Ability of subject to understand character and individual consequences of clinical trial * Written informed consent must be available before enrollment in the trial * For women with childbearing potential, adequate contraception (Pearl Index \< 1%, e.g. birth control pill) and negative blood pregnancy test * 6,5%\< HbA1c ≤ 9% * Ability of subject to understand character and individual consequences of clinical trial * Written informed consent must be available before enrollment in the trial * For women with childbearing potential, adequate contraception (Pearl Index \< 1%, e.g. birth control pill) and negative blood pregnancy test Exclusion Criteria: * MODY * Malignant disease * Hematopoietic disorders * Impairment of renal function (Serum creatinine \> 1,5mg/dl) * autoimmune disease * treatment with immunosuppressive drugs * Psychiatric disease * Myocardial ischemia during previous 6 month * Acute coronary syndrome * pAVK IIb, III, IV (Fontaine-Ratschow) * Erythropoietin treatment * Glitazone treatment during two weeks before inclusion * Insulin treatment during two weeks before inclusion * Pregnancy and lactation * History of hypersensitivity to the investigational product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational product * Participation in other clinical trials and observation period of competing trials, respectively * No subject will be allowed to enroll in this trial more than once.